In general, the percentage of individuals with abnormal levels of one or more of EGFR or EGFR ligands in serum were found to be nearly twice as high in the breast cancer group compared to the healthy control group (35.9% and 19.5%, respectively). Here, EGFR is linked to breast carcinoma.